Kaposi's sarcoma;Le sarcome de Kaposi

Bulletin du Cancer

Volumn 90, Issue 5, 2003, Pages 393-398

  Boué, François ^a   Lebbé, Céleste ^b  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

HHV8; HIV; Kaposi's sarcoma

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAYELIX; CIDOFOVIR; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FOSCARNET; GANCICLOVIR; PACLITAXEL; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

AFRICA; CANCER DIAGNOSIS; CANCER INCIDENCE; CELL PROLIFERATION; CLINICAL FEATURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KAPOSI SARCOMA; MALE; RECIPIENT; REVIEW; SOUTHERN EUROPE; SPINDLE CELL; SUPERINFECTION; VIRUS CARCINOGENESIS; DIFFERENTIAL DIAGNOSIS; INCIDENCE; PATHOGENICITY; PATHOLOGY; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; INCIDENCE; SARCOMA, KAPOSI;

EID: 0042205841     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. Arch Dermatol Syphil 1872; 4: 265-73.
2. Taylot JF, Templeton AC, Vogel CL, Zieglet JL, Kyalwazi SK. Kaposi's sarcoma in Uganda: a clinico-pathological study. Int J Cancer 1971; 8: 122-35.
3. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997; 64: 669-73.
4. Friedman-Kien AE, Laubenstein LJ, Rubinstein P, Buimovici-Klein E, Marmor M, Stahl R, et al. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982; 96: 693-700.
5. Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi's sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993; 28: 371-95.
6. Mitsuyasu RT. Kaposi's sarcoma in the acquired immunodeficiency syndrome. Infect Dis Clin North Am 1988; 2: 511-23.
7. Myskowski PL, Niedzwiecki D, Shurgot BA, Kaufman D, Krown SE, Nisce L, et al. AIDS-associated Kaposi's sarcoma: variables associated with survival. J Am Acad Dermatol 1988; 18: 1299-306.
8. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Ontology Committee. J Clin Oncol 1989; 7: 1201-7.
9. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15: 3085-92.
10. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999; 96: 4546-51.
11. Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999; 79: 243-51.
12. Bisceglia M, Bosman C, Quirke P. A histologic and flow cytometric study of Kaposi's sarcoma. Cancer 1992; 69: 793-8.
13. Roth WK, Brandstetter H, Sturzl M. Cellular and molecular features of HIV-associated Kaposi's sarcoma. AIDS 1992; 6: 895-913.
14. Delabesse E, Oksenhendlet E, Lebbe C, Verola O, Varet B, Tuthan AG. Molecular analysis of clonality in Kaposi's sarcoma. J Clin Pathol 1997; 50: 664-8.
15. Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 1997; 336: 988-93.
16. Gill PS, Tsai YC, Rao AP, Spruck CH, 3rd, Zheng T, Hatrington WA, et al. Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc Natl Acad Sci USA 1998; 95: 8257-61.
17. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-9.
18. Schulz TE, Sheldon J, Greensill J. Kaposi's sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8). Virus Res 2002; 82: 115-26.
19. Sarid R, Olsen SJ, Moore PS. Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res 1999; 52: 139-232.
20. Zong JC, Ciufo DM, Alcendor DJ, Wan X, Nicholas J, Browning PJ, et al. High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. J Virol 1999; 73: 4156-70.
21. Poole LJ, Zong JC, Ciufo DM, Alcendor DJ, Cannon JS, Ambinder R, et al. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the tight-hand end. J Virol 1999; 73: 6646-60.
22. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999; 93: 4034-43.
23. Boshoff C, Endo Y, Collins PD, Takeuchi Y, Reeves JD, Schweickart VL, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278: 290-4.
24. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998; 391: 86-9.
25. Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska T, Godden K, et al. Cyclin encoded by KS herpesvirus. Nature 1996; 382: 410.
26. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. Biology of Kaposi's sarcoma. Eur J Cancer 2001; 37: 1251-69.
27. Merat R, Amara A, Lebbe C, de The H, Morel P, Saib A. HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation. Int J Cancer 2002; 97: 791-5.
28. Huang LM, Chao MF, Chen MY, Shih H, Chiang YP, Chuang CY, et al. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem 2001; 276: 13427-32.
29. Vatthakavi V, Smith RM, Deng H, Sun R, Spearman P. Human immunodeficiency virus type-1 activates lyric cycle replication of Kaposi's sarcoma-associated herpesvirus through induction of KSHV Rta. Virology 2002; 297: 270-80.
30. Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117: 858-63.
31. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12: F45-9.
32. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-30.
33. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002; 22: 295-303.
34. Lassoued K, Clauvel JP, Katlama C, Janier M, Picard C, Matheron S. Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent. Cancer 1990; 66: 1869-72.
35. Volberding PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103: 335-8.
36. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomised phase III clinical trial. J Clin Oncol 1998; 16: 2445-51.
37. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus associated Kaposi's sarcoma. J Clin Oncol 1998; 16: 1112-21.
38. Boue F, Zaikas G, Lancar R, Caumes E, Lebbe C, Milpied-Homsi B, the Kaposi group of the AC5 ANRS, et al. Actvity of Taxotere (docetaxel) as therapy for pretreated HIV associated kaposi sarcoma: an ANRS Trial. J Clin Oncol 1998; 17 [ASCO proceedings 47a].
39. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593-602.
40. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratnet L, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002; 20: 153-9
41. Miles SA, Dezube BJ, Lee JY, Krown SE, Fletcher MA, Saville MW, et al. AIDS Malignancy Consortium. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002; 16: 421-9.
42. Miles SA, Testa M, Huang J, Wade M, Carden J, Scadden DT. Lack of antitumor activity and intolerance of interleukin-4 in patients with advanced HIV disease and Kaposi's sarcoma. J Interferon Cytokine Res 2002; 22: 1143-8.
43. Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis 2003; 187: 149-53.